Regeneron pharmaceuticals (regn) faces securities class action after losing $9 billion value following q3 2024 earnings report – hagens berman

San francisco, jan. 24, 2025 (globe newswire) -- regeneron pharmaceuticals, inc. (nasdaq: regn) faces a securities fraud class action after shares of the company plunged $84.59 on oct. 31, 2024, wiping out about $9 billion of market value.
REGN Ratings Summary
REGN Quant Ranking